# A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT01318421** · PHASE1 · TERMINATED · sponsor: **Elan Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** ELND002

## Key facts

- **NCT ID:** NCT01318421
- **Lead sponsor:** Elan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318421, "A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01318421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*